Prostate Cancer

A real-world analysis found that achieving a PSA level below 0.2 ng/mL was associated with improved overall survival in mCSPC.

These FAQs highlight key recommendations and practical takeaways from the 2026 AUA/ASTRO Clinically Localized Prostate Cancer guideline amendment.

The phase 3 PSMAddition trial found that adding lutetium Lu 177 vipivotide tetraxetan to ADT and an ARPI significantly improved rPFS in mHSPC.

A recap of the FDA submissions and regulatory decisions in urology from July 2026.

Four Urology Times Clinical Forums show that ARPI safety, drug interactions, and cognitive effects, not efficacy alone, guide mCSPC therapy selection.

The approval is supported by data from the phase 3 PSMAddition trial.

A 10-year registry analysis found focal HIFU and cryotherapy achieved durable cancer control and low prostate cancer mortality in localized disease.

This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.

CAPTAIN trial data showed TULSA preserved penile length, continence, and erectile function compared with robotic prostatectomy in localized prostate cancer.

The PDUFA target action date is in the fourth quarter of 2026.

Olaparib's indications in the US include use as a single agent for patients with HRR gene-mutated mCRPC and in combination with abiraterone and prednisone for patients with BRCA-mutated mCRPC.

These results provided the basis for the ongoing randomized phase 3 ProstACT Global trial evaluating 177Lu-rosopatamab tetraxetan in mCRPC.

The phase 2 study is assessing whether an adaptive treatment approach can improve responses and enable treatment pauses for select patients.

The pivotal phase 3 Himalayas-1 trial will evaluate rinzimetostat plus darolutamide vs with physician's choice of an ARPI or docetaxel.

According to the authors, the findings lay the groundwork for future work of genomics-guided treatment de-escalation in prostate cancer.

The phase 1 trial is assessing the safety and preliminary antitumor activity of actinium (225Ac) rhPSMA-10.1 injection.

A recent meta-analysis suggests that the Prolaris combined clinical risk score is prognostic across NCCN risk groups in men with localized prostate cancer.

These results are intended to support a premarket approval submission for an expanded indication of the Vanquish device for the management of clinically localized prostate cancer.

Interim results from the phase 2 CONVERGE-01 trial showed encouraging antitumor activity and a manageable safety profile with Ac-225 rosopatamab tetraxetan in mCRPC.

Atish D. Choudhury, MD, PhD, discusses findings from the A-DREAM / Alliance A032101 trial evaluating treatment interruption following favorable response to combination ADT and ARPI therapy in mHSPC.

The tentative approval spans tablets in 40-mg, 80-mg, 120-mg, and 160-mg strengths.

The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline.

In this video, Isaac Y. Kim, MD, PhD, MBA, discusses why immunotherapy may ultimately represent the next major advance in prostate cancer treatment.

Fred Saad, MD, CQ, FRCS, FCAHS, discusses additional efficacy data from the phase 3 PSMAddition trial, evaluating the addition of 177Lu-PSMA-617 to standard of care ADT plus an ARPI in PMSA+ mHSPC.

Enzalutamide plus talazoparib showed promising clinical activity in high-volume mHSPC, although with a notable toxicity burden.